- Home
- DBVT vs ACRE Comparison
DBVT vs ACRE Comparison
Compare DBVT & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- ACRE
- Stock Information
- Founded
- DBVT 2002
- ACRE 2011
- Country
- DBVT France
- ACRE United States
- Employees
- DBVT N/A
- ACRE 2100
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- ACRE Real Estate Investment Trusts
- Sector
- DBVT Health Care
- ACRE Real Estate
- Exchange
- DBVT Nasdaq
- ACRE Nasdaq
- Market Cap
- DBVT 237.4M
- ACRE 270.6M
- IPO Year
- DBVT N/A
- ACRE 2012
- Fundamental
- Price
- DBVT $9.40
- ACRE $4.81
- Analyst Decision
- DBVT Buy
- ACRE Hold
- Analyst Count
- DBVT 4
- ACRE 7
- Target Price
- DBVT $14.81
- ACRE $5.50
- AVG Volume (30 Days)
- DBVT 41.9K
- ACRE 420.5K
- Earning Date
- DBVT 07-29-2025
- ACRE 08-05-2025
- Dividend Yield
- DBVT N/A
- ACRE 12.50%
- EPS Growth
- DBVT N/A
- ACRE N/A
- EPS
- DBVT N/A
- ACRE N/A
- Revenue
- DBVT $3,497,000.00
- ACRE $67,129,000.00
- Revenue This Year
- DBVT $1,700.53
- ACRE N/A
- Revenue Next Year
- DBVT $535.67
- ACRE N/A
- P/E Ratio
- DBVT N/A
- ACRE N/A
- Revenue Growth
- DBVT N/A
- ACRE 83.51
- 52 Week Low
- DBVT $2.21
- ACRE $3.35
- 52 Week High
- DBVT $12.78
- ACRE $7.99
- Technical
- Relative Strength Index (RSI)
- DBVT 52.73
- ACRE 55.85
- Support Level
- DBVT $9.00
- ACRE $4.76
- Resistance Level
- DBVT $10.12
- ACRE $4.94
- Average True Range (ATR)
- DBVT 0.57
- ACRE 0.12
- MACD
- DBVT 0.08
- ACRE -0.01
- Stochastic Oscillator
- DBVT 72.24
- ACRE 56.90
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.